Endoscopic screening and surveillance for Barrett's esophagus - Clinical implications

MedGenMed Medscape General Medicine

Volumn 8, Issue 2, 2006, Pages

  Barr, Hugh ^a   Kendall, Catherine ^a   Bazant Hegemark, Florian ^a   Moayyedi, Paul ^b   Shetty, G ^a   Stone, Nicholas ^a  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; CANCER STAGING; CHROMOENDOSCOPY; CLINICAL TRIAL; CONFOCAL MICROSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS SURGERY; FLUORESCENCE SPECTROSCOPY; GASTROESOPHAGEAL REFLUX; HEALTH CARE DELIVERY; HEALTH SURVEY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LIGHT SCATTERING; MALIGNANT TRANSFORMATION; METAPLASIA; METHODOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PREDICTION; RAMAN SPECTROMETRY; RISK FACTOR; SCREENING TEST; SURVIVAL; SYMPTOM; ADENOCARCINOMA; ESOPHAGUS TUMOR; PATHOLOGY; REVIEW;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; POPULATION SURVEILLANCE;

EID: 33745588253     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053. Abstract
2. Wei JT, Shaheen NJ. The changing epidemiology of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:112-127. Abstract
3. El Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Endoscopy Clin N Am. 2002;31:421-440.
4. Mason AC, Eloubeidi MA, el Serag HB. Temporal trends in survival of patients with esophageal adenocarcinoma. 1973-1997. Gastroenterology. 2001;122:A30.
5. Jankowski J, Harrison RF, Perry I, Balkwill F, Tselepis C. Seminar: Barrett's metaplasia. Lancet. 2000;356:2079-2085. Abstract
6. Jankowski J, Provenzale D, Moayyedi P. Oesophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology. 2002;122:588-590.
7. Fennerty MB. Endoscopic diagnosis and surveillance of Barrett's esophagus. Tech Gastrointest Endosc. 2005;7:89-94.
8. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut. 2003;52:1081-1084. Abstract
9. Jankowski J, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology. 2002;122:588-590.
10. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2002;183:274-279. Abstract
11. Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97:1888-1895. Abstract
12. Report of Working Party of the British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus, 2005.
13. Fountoulakis A, Zafirellis KD, Dolan K. Effect of surveillance for Barrett's oesophagus on oesophageal cancer. Br J Surg. 2004;91:997-1003. Abstract
14. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633-640. Abstract
15. Dulai GS. Surveying the case for surveillance. Gastroenterology. 2002;122:820-825. Abstract
16. Sharma P, McQuaid K, Dent J, et al. AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett's esophagus. Gastroenterology. 2004;127:310-330. Abstract
17. Moayyedi P. Should patients with GERD be screened once at least for Barrett's epithelium? Con: Patients with GERD should be screened once at least for Barrett's esophagus-medicine or magic? Am J Gastroenterol. 2004;99:2293-2295. Abstract
18. Sampliner RE. Should patients with GERD be screened once at least for Barrett's epithelium? Pro: The need to screen GERD patients for Barrett's esophagus - a greater yield than surveillance. Am J Gastroenterol. 2004;99:2291-2293. Abstract
19. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ. 2000;321:1252-1255. Abstract
20. Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am J Gastroenterol. 2002;97:1319-1327. Abstract
21. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2002;16:41-50. Abstract
22. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick M, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176-186. Abstract
23. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043-2053. Abstract
24. Barr H. The pathological implications of surveillance, treatment and surgery for Barrett's oesophagus. Current Diagnostic Pathology. 2003;9:242-251.
25. Couvelard A, Cauvin J-M, Goldfain D, Rotenberg A, Robasziewicz, Flejou J-F. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut. 2001;49:761-766. Abstract
26. Egger K, Meining A, Werner M, Hofler H, Classen M, Rosch T. Endoscopic measurement of Barrett's esophagus length is unreliable: a prospective comparative biopsy study. Z Gastroenterol. 2004;42:499-502. Abstract
27. Riddell RH, Goldman H, Ransohoff D. Dysplasia in inflammatory bowel disease. Standardised classification with provisional clinical application. Hum Pathol. 1983;14:931-966. Abstract
28. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 1988;19:166-178. Abstract
29. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994;25:982-993. Abstract
30. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251-255. Abstract
31. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett's oesophagus: A reaffirmation. Hum Pathol. 2001;32:368-378. Abstract
32. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut. 2002;51:671-676. Abstract
33. Alderson D. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma: another spanner in the works. Gut. 2002;51:620-621. Abstract
34. Barr H. Photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Tech Gastrointest Endosc. 2005;7:60-65.
35. Sonnenberg A, Fennerty MB. Medical decision analysis of chemoprevention against adenocarcinoma. Gastroenterology. 2003;124:1758-1766. Abstract
36. Triadafilopoulos G, Kaur B, Sood S, Traxler B, Levine D, Westons A. The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus. Aliment Pharmacol Ther. 2006;23:997-1005. Abstract
37. Panjepour M, Overholt BF, Vo-Dinh T, Haggitt RC, Edwards DH, Buckley FP. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 1996;111:93-111. Abstract
38. Ortner M-A, Ebert B, Hein E, et al. Time gated fluorescence spectroscopy in Barrett's oesophagus. Gut. 2003;52:28-33. Abstract
39. Tunnell JW, Desjardins AE, Galindo L, et al. Instrumentation for multi-modal spectroscopic diagnosis of epithelial dysplasia. Technol Cancer Res Treat. 2003;2:505-514. Abstract
40. Egger K, Werner M, Meining A, et al. Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut. 2003;52:18-23. Abstract
41. Sharma P, Weston AP, Topalovski M, et al. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut. 2003;52:24-27. Abstract
42. Polglase AL, McLaren WJ, Skinner SA, Kiesslich R, Neurath MF, Delaney PM. A fluorescence confocal endomicroscope for in vivo microscopy of the upper and lower-GI tract. Gastrointest Endoscopy. 2005;62:686-695.
43. Tearney GJ, Brezinski ME, Bouma BE. In vivo endoscopic optical biopsy with optical coherence tomography. Science. 1997;276:2037-2039. Abstract
44. Hsiung P-L, Pantanowitz L, Aaron D, et al. Ultrahigh-resolution and 3-dimensional optical coherence tomography ex vivo imaging of the large and small intestines. Gastrointest Endosc. 2005;62:561-574. Abstract
45. Poneros JM, Brand S, Bouma BE, et al. Diagnosis of specialized intestinal metaplasia by optical coherence tomography. Gastroenterology. 2001;120:7-12. Abstract
46. Wong Kee Song L-M, Wilson BC. Optical detection of high-grade dysplasia in Barrett's esophagus. Tech Gastrointest Endosc. 2005;7:78-88.
47. Wallace MB, Perelman LT, Backman V, et al. Endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattering spectroscopy. Gastroenterology. 2000;119:677-682. Abstract
48. Stone N, Kendall C, Shepherd N, Crow P, Barr H. Near-infrared spectroscopy for classification of epithelial pre-cancers and cancers. J Raman Spectrosc. 2002;33:564-573.
49. Kendall C, Stone N, Shepherd N, et al. Raman spectroscopy a potential tool for the objective identification and classification of neoplasia in Barrett's oesophagus. J Pathol. 2003;200:602-609. Abstract
50. Hamamoto Y, Endo T, Nosho K, et al. Usefulness of narrow-band imaging endoscopy for diagnosis of Barrett's esophagus. J Gastroenterol. 2004;39:14-20. Abstract
51. Panjepour M, Overholt BF, Vo-Dinh T, et al. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 1996;111:93-101. Abstract
52. Loft DE, Alderson D, Heading RC. Screening and surveillance in columnar-lined oesophagus. British Society of Gastroenterology, Working Party Report. 2005;28:28-31.
53. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett's esophagus and esophageal cancer. JAMA. 2002;287:1972-1981. Abstract
54. Csendes A, Smok G, Burdiles P, et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus. 2000;13:5-11. Abstract
55. Sampliner RE. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97:1888-1895. Abstract
56. Dulai GS. Surveying the case for surveillance. Gastroenterology. 2002;122:820-825. Abstract
57. Barr H. Endoscopic surveillance of patients with Barrett's oesophagus. Gut. 2002;51:313-314. Abstract
58. Playford RJ. Endoscopic surveillance of patients with Barrett's oesophagus. Gut. 2002;314-315.
59. Corley DA, Levin TR, Weiss NS, Buffer PA. Surveillance and survival in Barrett's adenocarcinoma: a population-based study. Gastroenterology. 2002;122:633-640. Abstract
60. Tremble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excessive gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GERD. Gut. 1995;37:7-12. Abstract
61. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's oesophagus. Gastroenterology. 1993;105:40-50. Abstract
62. Povenzale D, Shmitt C, Wong J. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043-2053. Abstract